Cargando…

Osteolytic changes around biodegradable cement restrictors in hip surgery

BACKGROUND AND PURPOSE: Biodegradable cement restrictors are widely used in hip arthroplasty. Like others, we observed osteolytic reactions associated with a specific cement restrictor (SynPlug; made of PolyActive) and reviewed our patients. PATIENTS AND METHODS: We identified 703 patients with suit...

Descripción completa

Detalles Bibliográficos
Autores principales: Erschbamer, Matthias, Zdravkovic, Vilijam, Erhardt, Johannes, Öhlschlegel, Christian, Grob, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900087/
https://www.ncbi.nlm.nih.gov/pubmed/26905752
http://dx.doi.org/10.3109/17453674.2016.1152853
_version_ 1782436585241837568
author Erschbamer, Matthias
Zdravkovic, Vilijam
Erhardt, Johannes
Öhlschlegel, Christian
Grob, Karl
author_facet Erschbamer, Matthias
Zdravkovic, Vilijam
Erhardt, Johannes
Öhlschlegel, Christian
Grob, Karl
author_sort Erschbamer, Matthias
collection PubMed
description BACKGROUND AND PURPOSE: Biodegradable cement restrictors are widely used in hip arthroplasty. Like others, we observed osteolytic reactions associated with a specific cement restrictor (SynPlug; made of PolyActive) and reviewed our patients. PATIENTS AND METHODS: We identified 703 patients with suitable radiographs from our database (2007 to 2012) who underwent cemented hip arthroplasty and received a SynPlug biodegradable cement restrictor. We reviewed all available radiographs to determine the incidence, severity, and progression of osteolysis. Mean postoperative follow-up was 1.8 (1–7) years RESULTS: 1 year after implantation, the femoral cortex showed thinning by 12% in the anterior-posterior view and by 8% in the axial view. This had increased to 14% and 12%, respectively, at the latest available follow-up postoperatively (at a mean of 4 years). Cortical thinning of less than 10% was found in 37% of patients, but cortical thinning of 10–30% was found in 56% of patients. In the remaining 7%, a reduction of more than 30% of the original cortical thickness was observed. INTERPRETATION: Osteolytic changes associated with the SynPlug biodegradable bone restrictors are inconsistent and highly variable. While some patients showed increased weakening of the femoral cortex with the potential risk of periprosthetic fracture, in others the degree of osteolysis only increased slightly or stabilized after 2 or more years. Any cortical bone loss after total hip replacement should be avoided, so the use of PolyActive biodegradable cement restrictors should be discontinued. Patients with a PolyActive cement restrictor in place should be followed up closely after surgery.
format Online
Article
Text
id pubmed-4900087
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49000872016-06-22 Osteolytic changes around biodegradable cement restrictors in hip surgery Erschbamer, Matthias Zdravkovic, Vilijam Erhardt, Johannes Öhlschlegel, Christian Grob, Karl Acta Orthop Articles BACKGROUND AND PURPOSE: Biodegradable cement restrictors are widely used in hip arthroplasty. Like others, we observed osteolytic reactions associated with a specific cement restrictor (SynPlug; made of PolyActive) and reviewed our patients. PATIENTS AND METHODS: We identified 703 patients with suitable radiographs from our database (2007 to 2012) who underwent cemented hip arthroplasty and received a SynPlug biodegradable cement restrictor. We reviewed all available radiographs to determine the incidence, severity, and progression of osteolysis. Mean postoperative follow-up was 1.8 (1–7) years RESULTS: 1 year after implantation, the femoral cortex showed thinning by 12% in the anterior-posterior view and by 8% in the axial view. This had increased to 14% and 12%, respectively, at the latest available follow-up postoperatively (at a mean of 4 years). Cortical thinning of less than 10% was found in 37% of patients, but cortical thinning of 10–30% was found in 56% of patients. In the remaining 7%, a reduction of more than 30% of the original cortical thickness was observed. INTERPRETATION: Osteolytic changes associated with the SynPlug biodegradable bone restrictors are inconsistent and highly variable. While some patients showed increased weakening of the femoral cortex with the potential risk of periprosthetic fracture, in others the degree of osteolysis only increased slightly or stabilized after 2 or more years. Any cortical bone loss after total hip replacement should be avoided, so the use of PolyActive biodegradable cement restrictors should be discontinued. Patients with a PolyActive cement restrictor in place should be followed up closely after surgery. Taylor & Francis 2016-06 2016-02-18 /pmc/articles/PMC4900087/ /pubmed/26905752 http://dx.doi.org/10.3109/17453674.2016.1152853 Text en © 2016 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. https://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)
spellingShingle Articles
Erschbamer, Matthias
Zdravkovic, Vilijam
Erhardt, Johannes
Öhlschlegel, Christian
Grob, Karl
Osteolytic changes around biodegradable cement restrictors in hip surgery
title Osteolytic changes around biodegradable cement restrictors in hip surgery
title_full Osteolytic changes around biodegradable cement restrictors in hip surgery
title_fullStr Osteolytic changes around biodegradable cement restrictors in hip surgery
title_full_unstemmed Osteolytic changes around biodegradable cement restrictors in hip surgery
title_short Osteolytic changes around biodegradable cement restrictors in hip surgery
title_sort osteolytic changes around biodegradable cement restrictors in hip surgery
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900087/
https://www.ncbi.nlm.nih.gov/pubmed/26905752
http://dx.doi.org/10.3109/17453674.2016.1152853
work_keys_str_mv AT erschbamermatthias osteolyticchangesaroundbiodegradablecementrestrictorsinhipsurgery
AT zdravkovicvilijam osteolyticchangesaroundbiodegradablecementrestrictorsinhipsurgery
AT erhardtjohannes osteolyticchangesaroundbiodegradablecementrestrictorsinhipsurgery
AT ohlschlegelchristian osteolyticchangesaroundbiodegradablecementrestrictorsinhipsurgery
AT grobkarl osteolyticchangesaroundbiodegradablecementrestrictorsinhipsurgery